 |
| via necir.org |
Dr. Lockwood, Editor-in-Chief, is Dean of the Morsani College of Medicine and Senior Vice President of USF Health, University of South Florida, Tampa
"Our appreciation of the vast potential and major challenges posed by new genetic prenatal diagnostic testing seems to grow with each passing week. In particular, we now have a far better understanding of the utility and limitations of fetal cell-free DNA (cfDNA) testing and of expanded parental carrier testing.
Beyond the ethical and economic issues raised by these new diagnostic modalities, their rapid introduction into clinical practice raises practical management questions that obstetricians must now address.
Is cfDNA the best screening test for common fetal aneuploidies?
A recent article in The New England Journal of Medicine appears to definitively answer this question.1 Mary Norton and her colleagues reported the results of a large, industry-sponsored, prospective, blinded study comparing the effectiveness of cfDNA testing at 10 to 14 weeks with standard first-trimester screening using ultrasound nuchal translucency and maternal serum pregnancy-associated plasma protein A and human chorionic gonadotropin measurements for the detection of trisomies 21, 18, and 13.
Of 18,955 women seeking routine prenatal screening, 15,841 were available for analysis with both screening modalities..."
http://contemporaryobgyn.modernmedicine.com/contemporary-obgyn/news/promise-and-peril-new-prenatal-diagnostic-technologies
No comments:
Post a Comment